Scarica l'app Stockscreener
32.13
1.74%
-0.57
Dopo l'orario di chiusura:
32.22
0.09
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics Aims High at $92 Target, But Clinical Risks Remain - NAI500
Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors - Yahoo! Finance Canada
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. - The Motley Fool
NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3 - Stocktwits
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Viking Therapeutics options flow signals binary event bet ahead of VK2735 readout - Investing.com
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Eastern Progress
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
VKTX Stock On Track For Five Consecutive Days Of Gains — Viking Launches Human Trial For Novel Obesity Drug VK3019 - Stocktwits
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. - The Motley Fool
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits
Viking Therapeutics (VKTX) Gains Ahead Of Earnings As Its Obesity Narrative Keeps Fair Value In Focus - simplywall.st
Is Viking Therapeutics (VKTX) Stock Fully Priced After A 411% Run? - Yahoo! Finance Canada
Viking Therapeutics Inc. (VKTX) Peer Comparison – Compare with Others - Value Research
VKTX Stock Price, Quote & Chart - ChartMill
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong - The Motley Fool
Viking Therapeutics to present at three major h... - Pluang
Viking Therapeutics to Participate at Upcoming Investor Conferences - PR Newswire
Will Upcoming Oral VK2735 Late-Stage Trials Change Viking Therapeutics' (VKTX) Obesity Drug Narrative? - simplywall.st
Viking Therapeutics (VKTX) Stock Still Looks Stretched After A 382% Run - simplywall.st
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. - The Motley Fool
Viking Therapeutics (VKTX) On VK2735 Progress Is Valuation Running Ahead Of The Story - simplywall.st
Viking Therapeutics Stock (VKTX) Opinions on Phase 3 Obesity Drug Data Timing - Quiver Quantitative
6,189,649 Shares in Viking Therapeutics, Inc. $VKTX Purchased by BlackRock Inc. - InsuranceNewsNet
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? - The Motley Fool
VKTX Stock Steady After-Hours On Positive Obesity Drug Pipeline Progress - Stocktwits
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research - MarketBeat
Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In - simplywall.st
Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX - MarketBeat
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – NASDAQ:VKTX - TradingView
Viking Therapeutics Inc (VKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):